Petros Pharmaceuticals(PTPI)
$0.00+0.00 (+20.00%)
PTPI
Petros Pharmaceuticals financials statements
$0.00
At close:+0.00 (+20.00%)
Petros Pharmaceuticals (PTPI) Ratios
199 Followers
Petros Pharmaceuticals Ratios
PTPI's free cash flow for Q2 2026 was $-863.86K. For the 2026 fiscal year, PTPI's free cash flow was increased by $0.00 and operating cash flow was $-863.86K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.25 | 0.40 | 1.89 | 2.08 | 0.99 |
| Quick Ratio | 2.25 | 0.24 | 1.74 | 1.82 | 0.97 |
| Cash Ratio | 2.24 | 0.21 | 1.24 | 1.33 | 0.77 |
| Solvency Ratio | 0.83 | -0.63 | -0.22 | -0.91 | -0.07 |
| Operating Cash Flow Ratio | -2.94 | -0.14 | -0.71 | -1.81 | -0.38 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -0.36 | -6.59 | -11.74 | 0.00 |
| Net Current Asset Value | $ 2.87M | $ -10.81M | $ -925.38K | $ -1.05M | $ -1.30M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.69 | 0.24 | 0.30 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | -0.99 | 0.66 | 0.59 | 0.01 |
| Debt-to-Capital Ratio | 0.00 | -90.87 | 0.40 | 0.37 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.35 | 0.33 | 0.00 |
| Financial Leverage Ratio | 1.80 | -1.42 | 2.71 | 1.94 | 1.90 |
| Debt Service Coverage Ratio | 0.00 | -1.38 | -2.49 | -8.14 | -4.72 |
| Interest Coverage Ratio | 0.00 | -31.52 | -25.40 | -33.41 | -48.96 |
| Debt to Market Cap | 0.00 | 0.09 | 0.18 | 0.08 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.99 | 6.85 | 5.06 | 0.71 |
| Net Debt to EBITDA | 1.14 | -0.34 | 1.20 | -0.03 | 13.47 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 76.28% | 71.98% | 61.79% | 79.52% |
| EBIT Margin | 0.00% | -269.13% | -131.00% | -324.46% | -110.33% |
| EBITDA Margin | 0.00% | -211.54% | -72.34% | -229.06% | -22.28% |
| Operating Profit Margin | 0.00% | -345.84% | -233.88% | -332.37% | -231.05% |
| Pretax Profit Margin | 0.00% | -280.10% | -140.20% | -334.40% | -115.05% |
| Net Profit Margin | 0.00% | -280.10% | -140.20% | -334.40% | -115.05% |
| Continuous Operations Profit Margin | 0.00% | -280.10% | -140.20% | -334.40% | -115.05% |
| Net Income Per EBT | -42.52% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 96.96% | 80.99% | 59.95% | 100.61% | 49.79% |
| Return on Assets (ROA) | 37.06% | -134.63% | -24.15% | -61.80% | -13.34% |
| Return on Equity (ROE) | 66.66% | 191.75% | -65.41% | -119.97% | -25.28% |
| Return on Capital Employed (ROCE) | -161.67% | 239.16% | -59.14% | -78.55% | -49.57% |
| Return on Invested Capital (ROIC) | -161.67% | 21749.66% | -56.02% | -74.91% | -49.57% |
| Return on Tangible Assets | 37.06% | -192.69% | -32.88% | -99.31% | -21.35% |
| Earnings Yield | 85.23% | -18.11% | -18.01% | -16.62% | -0.99% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 12.29 | 2.62 | 2.84 | 2.55 |
| Payables Turnover | 0.00 | 0.52 | 0.95 | 1.27 | 0.35 |
| Inventory Turnover | 0.00 | 0.40 | 1.01 | 1.26 | 3.08 |
| Fixed Asset Turnover | 0.00 | 37.40 | 22.81 | 15.07 | 14.88 |
| Asset Turnover | 0.00 | 0.48 | 0.17 | 0.18 | 0.12 |
| Working Capital Turnover Ratio | 0.00 | -9.18 | 0.68 | 1.67 | -0.95 |
| Cash Conversion Cycle | 0.00 | 231.38 | 116.54 | 129.93 | -778.30 |
| Days of Sales Outstanding | 0.00 | 29.71 | 139.56 | 128.54 | 143.19 |
| Days of Inventory Outstanding | 0.00 | 902.65 | 360.34 | 289.38 | 118.58 |
| Days of Payables Outstanding | 0.00 | 700.97 | 383.36 | 287.99 | 1040.07 |
| Operating Cycle | 0.00 | 932.35 | 499.89 | 417.93 | 261.77 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.02 | -0.32 | -5.93 | -6.18 | -10.89 |
| Free Cash Flow Per Share | -0.02 | -0.33 | -5.93 | -6.18 | -10.89 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | -105.87 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | -0.35 | -0.92 | -1.29 | -29.29 |
| Operating Cash Flow to Sales Ratio | 0.00 | -0.51 | -1.31 | -2.14 | -1.52 |
| Free Cash Flow Yield | -299.96% | -3.32% | -16.83% | -10.61% | -1.31% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.01 | -2.95 | -5.55 | -6.02 | -100.88 |
| Price-to-Sales (P/S) Ratio | 0.00 | 15.46 | 7.78 | 20.12 | 116.06 |
| Price-to-Book (P/B) Ratio | 0.78 | -10.59 | 3.63 | 7.22 | 25.50 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.33 | -30.09 | -5.94 | -9.42 | -76.43 |
| Price-to-Operating Cash Flow Ratio | -0.33 | -30.37 | -5.94 | -9.42 | -76.43 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.06 | 0.16 | -0.35 | 1.28 |
| Enterprise Value Multiple | 0.64 | -7.65 | -9.56 | -8.82 | -507.54 |
| Enterprise Value | -2.89M | 82.73M | 40.27M | 121.05M | 883.13M |
| EV to EBITDA | 0.64 | -7.65 | -9.56 | -8.82 | -507.54 |
| EV to Sales | 0.00 | 16.18 | 6.92 | 20.20 | 113.06 |
| EV to Free Cash Flow | 0.43 | -31.49 | -5.28 | -9.46 | -74.45 |
| EV to Operating Cash Flow | 0.43 | -31.78 | -5.28 | -9.46 | -74.45 |
| Tangible Book Value Per Share | 0.01 | -1.33 | 2.73 | 2.15 | 9.41 |
| Shareholders’ Equity Per Share | 0.01 | -0.93 | 9.71 | 8.07 | 32.64 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.64 | 4.53 | 2.89 | 7.17 |
| Net Income Per Share | 0.01 | -1.78 | -6.35 | -9.68 | -8.25 |
| Tax Burden | -0.43 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.04 | 1.07 | 1.03 | 1.04 |
| Research & Development to Revenue | 0.00 | 0.51 | 0.41 | 0.29 | 0.23 |
| SG&A to Revenue | 0.00 | 1.71 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.04 | 0.07 | 0.20 | 0.17 |
| Income Quality | -2.72 | 0.18 | 0.93 | 0.64 | 1.32 |
Currency in USD

